Lifecore Biomedical, Inc
Lifecore Biomedical is a U.S.-based contract development and manufacturing organization that makes and fills complex sterile injectable pharmaceutical products and medical device products under contract for other companies. The business is centered in Chaska, Minnesota and combines hyaluronic acid manufacturing with aseptic fill-finish, formulation, and development services across syringes, vials, and cartridges.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment, tech transfer, and commercial production of sterile injectable products for customers.
Aseptic filling of injectable drug and device products into syringes, vials, and cartridges.
Non-animal-sourced hyaluronic acid produced in bulk and for formulated injectable products.
Analytical, formulation, validation, and scale-up services that support product launches.
Products
Reported · share of revenue- Contract Development and Manufacturing Organization69.9 %
- HA Manufacturing30.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Lifecore sells primarily to biopharmaceutical and biotechnology companies that need a contract partner for development and sterile manufacturing of injectable products. It also serves customers in medical-device and specialty healthcare markets, including programs tied to ophthalmic, orthopedic, wound care, aesthetics, and drug-delivery applications. Customers choose Lifecore for its ability to take a product from development through commercial fill-finish while managing regulatory and quality requirements. Academic and corporate research customers also appear in the pipeline for certain HA-related and development work.
Buy development, tech transfer, and commercial fill-finish for injectable drug programs.
Buy clinical and early commercial manufacturing for novel injectable therapies.
Buy aseptic manufacturing and fill-finish for syringe, vial, and cartridge products.
Buy HA raw material and formulation support for ophthalmic, orthopedic, and specialty uses.
Buy development services and material supply for exploratory HA and injectable work.
Strategy
Lifecore's strategy is to expand its CDMO pipeline by winning new sterile injectable programs, converting development work into commercial manufacturing, and broadening beyond its traditional HA base. It is also focused on improving manufacturing capacity, quality systems, and operational efficiency so that it can handle more complex programs and support higher customer demand. The company uses its vertically integrated model to offer a broader service package, from raw material supply through aseptic fill-finish and supply-chain responsibility. That combination is meant to make it a more durable partner for sponsors needing speed, regulatory discipline, and technical depth.
A broader pipeline increases future manufacturing volume and customer diversification.
Commercialized programs create recurring manufacturing demand and deeper customer relationships.
More capacity allows the company to pursue larger and more complex injectable opportunities.
Better execution supports sponsor confidence, lower unit costs, and stronger manufacturing reliability.
Geography
Lifecore is headquartered and operates in the United States, with manufacturing concentrated in its cGMP facilities in Chaska, Minnesota. Its customer base is global, supported by certifications and regulatory experience in Europe, Japan, Brazil, and other major markets. The business is exposed to cross-border regulatory requirements because many customer products are sold internationally and must clear multiple health authorities. Geography matters mainly through where the plants sit, where customers launch products, and which regulators oversee each program.
Risks
Lifecore is exposed to regulatory and manufacturing risks because it produces sterile injectable products under cGMP requirements and depends on passing inspections by the FDA and other agencies. It also relies on customers obtaining and keeping product approvals, so delays, recalls, or launch failures at sponsor companies can reduce demand for its services. The company faces customer concentration, execution, and financing risk common to CDMOs, especially when adding complex programs that require capital, validation, and reliable throughput. Competition for specialized sterile-fill capacity and any quality issue at the plant level could materially affect future business wins and customer retention.
- cGMP compliance and regulatory inspection riskImpact: HighLikelihood: High
Sterile manufacturing is heavily regulated and adverse findings can interrupt production or trigger remediation.
Exposure: FDA and other global regulators
- Customer product approval dependenceImpact: HighLikelihood: High
Revenue depends on sponsors obtaining approvals for the products Lifecore manufactures for them.
Exposure: Clinical and commercial programs
- Manufacturing quality or contamination eventsImpact: HighLikelihood: Medium
Aseptic fill-finish requires strict control; defects can lead to recalls, downtime, or lost customers.
Exposure: Sterile injectable production
- Customer concentration and sponsor funding riskImpact: MediumLikelihood: High
Program delays or sponsor funding shortfalls can reduce orders and backlog conversion.
Exposure: Development and commercial customers
- Execution risk on new capacity and programsImpact: MediumLikelihood: Medium
Complex fill-finish lines and new site transfers require validation, staffing, and process discipline.
Exposure: New commercial programs
Accounting
Judgemental itemsContracts span development, validation, and manufacturing, so timing of performance obligations affects reported revenue.
Impact: Can shift revenue between periods as programs progress
Aseptic filling and capacity investments require significant capital spending and asset lives matter to expense recognition.
Impact: Affects gross margin and operating expense trends
Complex sterile products and HA manufacturing require judgment on usable inventory and project-specific costs.
Impact: Can affect margin and inventory valuation
Manufacturing assets and acquired facilities must be tested if expected cash flows weaken.
Impact: Could create non-cash charges
Preferred stock, credit facilities, and stock issuance history require careful classification and measurement.
Impact: Affects leverage presentation and earnings per share
Similar listed companies
Publicly listed companies with a comparable business focus.
Xencor Inc
XNCR · Pharmaceutical Preparations
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Last updated: 28/09/2026